NCT04603001 2025-06-27Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting260 enrolled
NCT05107856 2024-01-31PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesPrelude TherapeuticsPhase 1 Terminated21 enrolled